It also inhibits other RTKs associated with pathogenic tumor angiogenesis, tumor cell growth, and tumor development for normal cellular functions, including fibroblast growth factor receptors (FGFR) 1, 2, 3 and 4, KIT, platelet-derived growth factor receptor-α/β (PDGFR-α/β) and RET [16,17]. The gene discussed is KIT; the disease is neoplasm.